Skip to main content
SpringerLink
Log in

Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma

  • Clinical Studies
  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sigel CW, Macklin AW, Woolley JL Jr, Johnson MW, Collier MA, Blum MR, Clendennin NJ, Everitt BJM, Grebe G, Mackars A, Foss RG, Duch DS, Bowers SW, Nichol CA: Preclinical Biochemical Pharmacology and Toxicology of Piritrexim, a Lipophilic Inhibitor of Dihydrofolate Reductase. NCI Monograph 5:111–120, 1987

    Google Scholar 

  2. Laszlo J, Brenkman WD Jr, Morgan E, Clendennin NJ, Williams T, Currie V, Young C: Initial Clinical Studies of Piritrexim. NCI Monograph 5:121–125, 1987

    Google Scholar 

  3. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MHN: Selective Toxicity of a New Lipophilic Antifolate, BW301U, for Methotrexate-Resistant Cells with Reduced Drug Uptake. Cancer Res 45:978–982, 1985

    Google Scholar 

  4. Carabasi M, Magill GB, Casper ES, Marks L, Cheng EW: A Phase II trial of oral piritrexim for advanced sarcomas in adults. Proc ASCO 7:276, 1988

    Google Scholar 

  5. Kane MJ: Chemotherapy of Advanced Soft Tissue and Osteosarcomas. Sem Onc 16:297–304, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Synertron, Inc., Madison, WI, USA

    Judith D. Schiesel & Richard V. Smalley

  2. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Matthew Carabasi, Gordon Magill, Ephraim Casper, Edgar Cheng & Linda Marks

  3. Burroughs Wellcome Co., Research Triangle Park, NC, USA

    Neil J. Clendeninn

  4. Univ. of Wisconsin Clinical Cancer Center, Madison, WI, USA

    Jan Feyzi & Richard V. Smalley

Authors
  1. Judith D. Schiesel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Carabasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon Magill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ephraim Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edgar Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Linda Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jan Feyzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neil J. Clendeninn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Richard V. Smalley
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The study was sponsored by Burroughs Wellcome Co. and monitored and audited by Synertron, Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiesel, J.D., Carabasi, M., Magill, G. et al. Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma. Invest New Drugs 10, 97–98 (1992). https://doi.org/10.1007/BF00873124

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873124

Key words

Search

Navigation